ResearcherUniversity of British ColumbiaNo recent work listed

Süheda Erener

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4516-4028; OpenAlex author ID A5020486321. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2021: 1 paper

Papers 1

Deletion of pancreas-specific miR-216a reduces beta-cell mass and inhibits pancreatic cancer progression in mice. Co-author DOI 10.1016/j.xcrm.2021.100434 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Marina Lesina · 1 shared paper, 2021 · strength 0.10
- Paper Deletion of pancreas-specific miR-216a reduces beta-cell mass and inhibits pancreatic cancer progression in mice. DOI 10.1016/j.xcrm.2021.100434 ↗
Stephan Herzig · 1 shared paper, 2021 · strength 0.10
- Paper Deletion of pancreas-specific miR-216a reduces beta-cell mass and inhibits pancreatic cancer progression in mice. DOI 10.1016/j.xcrm.2021.100434 ↗
Janel L. Kopp · 1 shared paper, 2021 · strength 0.10
- Paper Deletion of pancreas-specific miR-216a reduces beta-cell mass and inhibits pancreatic cancer progression in mice. DOI 10.1016/j.xcrm.2021.100434 ↗
Timothy J. Kieffer · 1 shared paper, 2021 · strength 0.10
- Paper Deletion of pancreas-specific miR-216a reduces beta-cell mass and inhibits pancreatic cancer progression in mice. DOI 10.1016/j.xcrm.2021.100434 ↗
Hana Algül · 1 shared paper, 2021 · strength 0.10
- Paper Deletion of pancreas-specific miR-216a reduces beta-cell mass and inhibits pancreatic cancer progression in mice. DOI 10.1016/j.xcrm.2021.100434 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.